TABLE OF CONTENTS
1 INTRODUCTION 38
1.1 OBJECTIVES OF THE STUDY 38
1.2 MARKET DEFINITION 38
1.3 OVERVIEW OF THE NORTH AMERICA FLOW CYTOMETRY MARKET 38
1.4 LIMITATIONS 40
1.5 MARKETS COVERED 40
2 MARKET SEGMENTATION 43
2.1 MARKETS COVERED 43
2.2 GEOGRAPHICAL SCOPE 44
2.3 YEARS CONSIDERED FOR THE STUDY 45
2.4 CURRENCY AND PRICING 45
2.5 DBMR TRIPOD DATA VALIDATION MODEL 46
2.6 MULTIVARIATE MODELLING 49
2.7 PRODUCT SEGMENT LIFELINE CURVE 49
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 50
2.9 DBMR MARKET POSITION GRID 51
2.10 MARKET APPLICATION COVERAGE GRID 52
2.11 VENDOR SHARE ANALYSIS 53
2.12 SECONDARY SOURCES 54
2.13 ASSUMPTIONS 54
3 EXECUTIVE SUMMARY 55
4 PREMIUM INSIGHTS 58
4.1 PORTERS FIVE FORCES 59
4.2 PESTEL ANALYSIS 60
5 MARKET OVERVIEW 61
5.1 DRIVERS 63
5.1.1 RISING PREVALENCE OF CHRONIC DISEASES 63
5.1.2 INCREASING APPLICATION OF CYTOMETRY INSTRUMENTS 64
5.1.3 INCREASE IN USE OF FLOW CYTOMETRY IN DRUG DISCOVERY 65
5.1.4 GROWTH IN STEM CELL RESEARCH AND ACQUISITION OF RECOMBINATION OF DNA TECHNOLOGIES 67
5.2 RESTRAINTS 68
5.2.1 HIGH COST OF FLOW CYTOMETRY INSTRUMENTS 68
5.2.2 LIMITATIONS OF FLOW CYTOMETRY 69
5.2.3 LACK OF SKILLED PROFESSIONALS 70
5.3 OPPORTUNITIES 71
5.3.1 INCREASE IN ADOPTION OF FLOW CYTOMETRY TECHNIQUES IN RESEARCH AND ACADEMIA 71
5.3.2 DEVELOPMENT IN PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES 72
5.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 73
5.3.4 DEVELOPING A PIPELINE OF STEM CELL RESEARCH 74
5.4 CHALLENGES 74
5.4.1 DIFFICULTY IN THE DEVELOPMENT AND VALIDATION OF FLOW CYTOMETRY ASSAYS 74
5.4.2 COMPLEXITIES RELATED TO REAGENT DEVELOPMENT 75
6 NORTH AMERICA FLOW CYTOMETRY MARKET, BY PRODUCT 77
6.1 OVERVIEW 78
6.2 REAGENTS AND CONSUMABLES 81
6.2.1 DYE 82
6.2.2 ANTIBODIES 82
6.2.3 BEADS 82
6.2.4 OTHERS 82
6.3 FLOW CYTOMETRY INSTRUMENTS 82
6.3.1 CELL ANALYZERS 83
6.3.1.1 CELL ANALYZERS, BY TYPE 84
6.3.1.1.1 IMAGING FLOW CYTOMETERS 84
6.3.1.1.2 NON-IMAGING FLOW CYTOMETERS 84
6.3.1.2 CELL ANALYZERS, BY MODALITY 84
6.3.1.2.1 BENCHTOP 84
6.3.1.2.2 STANDALONE 84
6.3.2 CELL SORTERS 85
6.3.2.1 BENCHTOP 85
6.3.2.2 STANDALONE 85
6.4 ACCESSORIES 85
6.4.1 FILTERS 86
6.4.2 DETECTORS 86
6.4.3 OTHERS 86
6.5 SERVICES 87
6.6 SOFTWARE 87
7 NORTH AMERICA FLOW CYTOMETRY MARKET, BY TECHNOLOGY 89
7.1 OVERVIEW 90
7.2 CELL-BASED FLOW CYTOMETRY 94
7.3 BEAD-BASED FLOW CYTOMETRY 95
8 NORTH AMERICA FLOW CYTOMETRY MARKET, BY APPLICATION 96
8.1 OVERVIEW 97
8.2 RESEARCH APPLICATIONS 101
8.2.1 CELL CYCLE ANALYSIS 102
8.2.2 CELL SORTING/SCREENING 102
8.2.3 CELL TRANSFECTION/VIABILITY 102
8.2.4 PHARMACEUTICAL AND BIOTECHNOLOGY 103
8.2.4.1 DRUG DISCOVERY 103
8.2.4.2 STEM CELL RESEARCH 103
8.2.4.3 IN VITRO TOXICITY TESTING 103
8.2.5 IMMUNOLOGY 103
8.2.6 APOPTOSIS 103
8.2.7 CELL COUNTING 103
8.2.8 OTHERS 103
8.3 CLINICAL APPLICATIONS 104
8.3.1 HAEMATOLOGY 105
8.3.2 CANCER 105
8.3.3 IMMUNODEFICIENCY DISEASES 105
8.3.4 ORGAN TRANSPLANTATION 105
8.3.5 OTHER CLINICAL APPLICATION 105
8.4 INDUSTRIAL APPLICATIONS 105
9 NORTH AMERICA FLOW CYTOMETRY MARKET, BY END USER 107
9.1 OVERVIEW 108
9.2 PHARMACEUTICALS & BIOTECHNOLOGY COMPANIES 111
9.3 ACADEMIC & RESEARCH INSTITUTES 112
9.4 HOSPITALS 113
9.5 CLINICAL TESTING LABORATORIES 114
9.6 BLOOD BANK 115
9.7 OTHERS 116
10 NORTH AMERICA FLOW CYTOMETRY MARKET, BY DISTRIBUTION CHANNEL 117
10.1 OVERVIEW 118
10.2 RETAIL SALES 121
10.3 DIRECT TENDERS 122
11 NORTH AMERICA FLOW CYTOMETRY MARKET, BY GEOGRAPHY 123
11.1 NORTH AMERICA 124
11.1.1 U.S. 133
11.1.2 CANADA 137
11.1.3 MEXICO 141
12 NORTH AMERICA FLOW CYTOMETRY MARKET, COMPANY LANDSCAPE 145
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 145
13 SWOT ANALYSIS 146
14 COMPANY PROFILE 147
14.1 THERMO FISHER SCIENTIFIC INC. 147
14.1.1 COMPANY SNAPSHOT 147
14.1.2 REVENUE ANALYSIS 148
14.1.3 COMPANY SHARE ANALYSIS 148
14.1.4 PRODUCT PORTFOLIO 149
14.1.5 RECENT DEVELOPMENTS 149
14.2 BD 151
14.2.1 COMPANY SNAPSHOT 151
14.2.2 REVENUE ANALYSIS 151
14.2.3 COMPANY SHARE ANALYSIS 152
14.2.4 PRODUCT PORTFOLIO 152
14.2.5 RECENT DEVELOPMENT 153
14.2.5.1 COLLABORATION 153
14.3 AGILENT TECHNOLOGIES, INC. 154
14.3.1 COMPANY SNAPSHOT 154
14.3.2 REVENUE ANALYSIS 154
14.3.3 COMPANY SHARE ANALYSIS 155
14.3.4 PRODUCT PORTFOLIO 155
14.3.5 RECENT DEVELOPMENTS 156
14.4 SARTORIUS AG 157
14.4.1 COMPANY SNAPSHOT 157
14.4.2 REVENUE ANALYSIS 157
14.4.3 COMPANY SHARE ANALYSIS 158
14.4.4 PRODUCT PORTFOLIO 158
14.4.5 RECENT DEVELOPMENT 159
14.5 NEXCELOM BIOSCIENCE LLC 160
14.5.1 COMPANY SNAPSHOT 160
14.5.2 PRODUCT PORTFOLIO 160
14.5.3 RECENT DEVELOPMENT 160
14.5.4 COMPANY SHARE ANALYSIS 161
14.6 APOGEE FLOW SYSTEMS LTD. 162
14.6.1 COMPANY SNAPSHOT 162
14.6.2 PRODUCT PORTFOLIO 162
14.6.3 RECENT DEVELOPMENT 162
14.7 BAY BIOSCIENCE CO., LTD. 163
14.7.1 COMPANY SNAPSHOT 163
14.7.2 PRODUCT PORTFOLIO 163
14.7.3 RECENT DEVELOPMENT 163
14.8 BIOMRIEUX 164
14.8.1 COMPANY SNAPSHOT 164
14.8.2 REVENUE ANALYSIS 165
14.8.3 PRODUCT PORTFOLIO 165
14.8.4 RECENT DEVELOPMENT 165
14.9 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER CORPORATION) 166
14.9.1 COMPANY SNAPSHOT 166
14.9.2 REVENUE ANALYSIS 166
14.9.3 PRODUCT PORTFOLIO 167
14.9.4 RECENT DEVELOPMENTS 168
14.9.4.1 ACQUISITION 168
14.9.4.2 PRODUCT LAUNCH 168
14.10 BENNUBIO INC. 170
14.10.1 COMPANY SNAPSHOT 170
14.10.2 PRODUCT PORTFOLIO 170
14.10.3 RECENT DEVELOPMENT 170
14.11 BIOLEGEND, INC. 171
14.11.1 COMPANY SNAPSHOT 171
14.11.2 PRODUCT PORTFOLIO 171
14.11.3 RECENT DEVELOPMENT 173
14.12 BIO-RAD LABORATORIES, INC. 174
14.12.1 COMPANY SNAPSHOT 174
14.12.2 REVENUE ANALYSIS 174
14.12.3 PRODUCT PORTFOLIO 175
14.12.4 RECENT DEVELOPMENT 175
14.13 CELL SIGNALING TECHNOLOGY, INC. 176
14.13.1 COMPANY SNAPSHOT 176
14.13.2 PRODUCT PORTFOLIO 176
14.13.3 RECENT DEVELOPMENT 177
14.14 CELLKRAFT BIOTECH PVT. LTD 178
14.14.1 COMPANY SNAPSHOT 178
14.14.2 PRODUCT PORTFOLIO 178
14.14.3 RECENT DEVELOPMENT 179
14.15 CYTEK BIOSCIENCES 180
14.15.1 COMPANY SNAPSHOT 180
14.15.2 PRODUCT PORTFOLIO 180
14.15.3 RECENT DEVELOPMENTS 181
14.15.3.1 PRODUCT LAUNCH 181
14.15.3.2 ACQUISITION 182
14.16 CYTOBUOY B.V. 183
14.16.1 COMPANY SNAPSHOT 183
14.16.2 PRODUCT PORTFOLIO 183
14.16.3 RECENT DEVELOPMENT 183
14.17 CYTONOME/ST, LLC 184
14.17.1 COMPANY SNAPSHOT 184
14.17.2 PRODUCT PORTFOLIO 184
14.18 COHERENT CORP. 185
14.18.1 COMPANY SNAPSHOT 185
14.18.2 REVENUE ANALYSIS 185
14.18.3 PRODUCT PORTFOLIO 186
14.18.4 RECENT DEVELOPMENTS 186
14.18.4.1 Announcement 186
14.18.4.2 PRODUCT LAUNCH 186
14.18.4.3 AWARDS 187
14.18.5 RECENT DEVELOPMENT 187
14.19 ELABSCIENCE BIOTECHNOLOGY INC. 188
14.19.1 COMPANY SNAPSHOT 188
14.19.2 PRODUCT PORTFOLIO 188
14.19.3 RECENT DEVELOPMENT 189
14.20 ENZO BIOCHEM INC. 190
14.20.1 COMPANY SNAPSHOT 190
14.20.2 REVENUE ANALYSIS 191
14.20.3 PRODUCT PORTFOLIO 191
14.20.4 RECENT DEVELOPMENT 191
14.21 IKEDA SCIENTIFIC CO., LTD. 192
14.21.1 COMPANY SNAPSHOT 192
14.21.2 PRODUCT PORTFOLIO 192
14.21.3 RECENT DEVELOPMENT 193
14.22 MERCK KGAA 194
14.22.1 COMPANY SNAPSHOT 194
14.22.2 REVENUE ANALYSIS 194
14.22.3 PRODUCT PORTFOLIO 195
14.22.4 RECENT DEVELOPMENT 195
14.23 MILTENYI BIOTEC 196
14.23.1 COMPANY SNAPSHOT 196
14.23.2 PRODUCT PORTFOLIO 196
14.23.3 RECENT DEVELOPMENT 198
14.23.3.1 PRODUCT LAUNCH 198
14.24 NANOCELLECT BIOMEDICAL 199
14.24.1 COMPANY SNAPSHOT 199
14.24.2 PRODUCT PORTFOLIO 199
14.24.3 RECENT DEVELOPMENTS 199
14.25 NEOGENOMICS LABORATORIES 201
14.25.1 COMPANY SNAPSHOT 201
14.25.2 REVENUE ANALYSIS 201
14.25.3 PRODUCT PORTFOLIO 202
14.25.4 RECENT DEVELOPMENT 202
14.26 ON-CHIP BIOTECHNOLOGIES CO., LTD. CORPORATION 203
14.26.1 COMPANY SNAPSHOT 203
14.26.2 PRODUCT PORTFOLIO 203
14.26.3 RECENT DEVELOPMENTS 203
14.27 ORFLO TECHNOLOGIES 204
14.27.1 COMPANY SNAPSHOT 204
14.27.2 PRODUCT PORTFOLIO 204
14.27.3 RECENT DEVELOPMENT 204
14.28 Q2 SOLUTION 205
14.28.1 COMPANY SNAPSHOT 205
14.28.2 REVENUE ANALYSIS 205
14.28.3 SERVICE PORTFOLIO 206
14.28.4 RECENT DEVELOPMENT 206

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.